February Newsletter




 

We are still basking in the glow of the Shine a Light on Duchenne Gala, what an event, and what an incredible show of support! During the gala, Jett Foundation announced our newest program, the Jett Giving Fund, dedicated to helping ease the financial burden of critical medical and accesibility equipment on families and patients affected by Duchenne. This new program is just one of the many ways Jett Foundation is working every day to fill the unmet needs in the Duchenne community.

Thank you for your continued support, together we are making a difference in Duchenne.
jett and christine

Best,
christine signature
Christine McSherry 
Jett Foundation Founder and Executive Director

P.S. February 28th is Rare Disease Day, consider making a donation in honor of someone you know affected by rare disease. #RareDiseaseDay2017



JETT GIVING FUND
Donate the difference.

Jett Foundation established the  Jett Giving Fund to assist families affected by Duchenne muscular dystrophy in purchasing unaffordable, but vital medical and accessibility equipment.  Contact us today to become a Jett Giving Fund supporter or applicant!  Learn More

 

EDUCATIONAL ROUNDTABLES
Education is power.

All are welcome to attend Jett Foundation's FREE  roundtables that bring resources and information on treatment options and clinical trials directly to families affected by Duchenne.Jett's  next two roundtables are on Feb. 11th in Long Island, NY and on March 4th in New Orleans, LA.   Learn More


Golf
JETT GOLF CLASSIC
Monday, June 5th at Black Rock Country Club, Hingham

Registration will be opening soon, mark your calendar, take the day off and get your foursome together!   Learn more.

Tri4Jett 2017
June 25th in Cohasset

The 2017 Tri for Jett Team is being captained by Craig Martin of The Goodale Company, Inc. -  Cohasset Insurance .  The Cohasset Triathlon sells out every year, to get your FREE spot, email Alissa Ford at  alissa@jettfoundation.org .   Learn more


JettRide 2017
July 12-28th -  Ohio to N.J.

Want to raise awareness and funds for Duchenne this summer in a fun, healthy, adventurous way? Join the 2017 JettRiders as they cycle from Ohio to New Jersey, white water rafting, sightseeing, and visiting with families affected by Duchenne the whole way!  Learn more

CAMP PROMISE
Making happy campers.

We're excited to welcome Shannon Healey, our newest Jett and Camp Promise team member. Welcome, Shannon!
Camper applications are flying in and will be processed on a rolling basis. So, start yours today!   Learn more


GALS FOR CAL
Challenge yourself, challenge Duchenne.

Gals for Cal will compete in the Title 9 Triathlon in Hopkinton on Sunday, September 10, 2017. 

For the men who also want to tri for Duchenne, the D.A.D.S. (Dudes Against Duchenne) are competing in the  Sharon Triathlon Max Performance  in Sharon, MA on August 13th. 

Email Cindy Quitzau, at galsforcal1@veizon.net to join a team !   Learn More


New Way to Donate!
Jett Foundation can now accept stock donations. Click below for a simple way to donate your stock to Jett Foundation.


The Latest Industry Partner News
Jett Foundation collaborates with industry partners who are developing potential treatments for Duchenne. Read more about their recent updates below. For additional information on clinical trials in Duchenne, please go to  clinicaltrials.gov


Sarepta Therapeutics announces it has entered an exclusive license agreement with Nationwide Children's Hospital, for their Galgt2 gene therapy program developed by researcher Dr. Paul Martin, Ph.D.

Akashi Therapeutics announces it  is working toward having three novel, complementary compounds in the clinic in 2017 with potential to treat all DMD patients independent of their specific genetic mutation.

PTC Therapeutics provides Corporate update

Catabasis Pharmaceuticals  reports positive pre clinical data

PTC Therapeutics  CHMP recommends renewal of Translarna's marketing authorization for nonsense mutation Duchenne muscular dystrophy based on continued positive benefit-risk assessment. 
 
Capricor Therapeutics to expand clinical development program in Duchenne muscular dystrophy. 
 
NS Pharma announces fast track designation to NS-065/NCNP-01 for the treatment of Duchenne.
 
Pfizer Duchenne program update